- Home
- CEPF vs OVID Comparison
CEPF vs OVID Comparison
Compare CEPF & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
N/A
Current Price
$2.47
Company Overview
Basic Information| Metric | CEPF | OVID |
|---|---|---|
| Founded | 2021 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 594.9M | 562.5M |
| IPO Year | 2025 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CEPF | OVID |
|---|---|---|
| Price | $10.28 | $2.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $6.02 |
| AVG Volume (30 Days) | 99.5K | ★ 1.4M |
| Earning Date | 01-01-0001 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.90 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,252,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $96.45 | ★ N/A |
| Revenue Growth | N/A | ★ 1181.27 |
| 52 Week Low | $10.13 | $1.18 |
| 52 Week High | $10.67 | $3.11 |
Technical Indicators
Market Signals| Indicator | CEPF | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 35.54 | 44.60 |
| Support Level | $10.26 | $2.38 |
| Resistance Level | $10.35 | $2.79 |
| Average True Range (ATR) | 0.02 | 0.14 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 14.29 | 31.30 |
Price Performance
Historical Comparison CEPF
OVID
About CEPF Cantor Equity Partners IV Inc. Class A Ordinary Shares
Cantor Equity Partners IV Inc is a blank check company.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.